Weekly Recap | DaVita this week, most brokers rate it buy
I'm LongbridgeAI, I can summarize articles.DaVita (DVA) finished the latest session at $183.99, trading within a narrow range of $179.95 to $184.13. Pre-market quotes touched a high of $185.73, but the regular session pulled back from that level. The S&P 500 added 0.09% this week; a comparison with DaVita cannot be calculated from the available data.
The Week
DaVita (DVA) finished the latest session at $183.99, trading within a narrow range of $179.95 to $184.13. Pre-market quotes touched a high of $185.73, but the regular session pulled back from that level. The S&P 500 added 0.09% this week; a comparison with DaVita cannot be calculated from the available data.
Key Events
The main company-specific news this week came on 2 September, when DaVita expanded its partnership with Humana. That led to a round of debate about whether the stock is still undervalued. The other items in the week’s feed were mostly intraday moves or broader market chatter, not material corporate announcements, so the Humana expansion stands out as the week’s core event.
Analyst Ratings
Seven brokers cover DaVita: three rate it buy, three rate it hold, and one rates it underperform. No firm has a sell or no-opinion rating. The consensus rating remains buy, with a consensus target price of $218.43, about 18.72% above the latest price of $183.99. The target range is wide, from $165.00 to $270.00, reflecting real disagreement. Within the healthcare services industry, DaVita ranks 26th out of 53 names.
The Week Ahead
The US releases several macro readings next week. On 8 September, the NFIB small business optimism index is due, with a prior reading of 99.8. On 10 September, initial jobless claims, PPI figures, and existing home sales will be in focus. These numbers are not DaVita-specific, but they carry weight for healthcare services and overall risk appetite. The market’s reaction to the Humana expansion also deserves monitoring.
In Short
DaVita’s week was quiet aside from the Humana partnership expansion, which revived the valuation debate. The broker picture skews positive, with a consensus target well above spot, yet the wide target range shows limited agreement. The latest capital snapshot shows large-lot money as a net buyer while small-lot money turned net seller. What matters next is whether the expanded partnership shows up in future volumes and how macro data feeds into healthcare services.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.